Multiple retrospective trials have shown that a high tTMB (determined with a cut-off >20 mut/mb in the CHECKMATE-026 trial) predicts a greater benefit of the PD-1 inhibitors nivolumab or pembrolizumab, in both treatment-naive and pretreated NSCLC patients [136,137,138]. Here, TMEM200B is linked to non-small cell lung carcinoma.